life scienc tool diagnost
beat slightli weaker revenu off-set stronger profit
factor line ad vs estimate encouragingli boost
ep guidanc midpoint greater beat
rais ep reflect latest upsid
well stronger top-line profit expect balanc
rev shi plan excl cc profit ahead solid btb
revenu rose cc slightli estim
post solid net book-to-bil reflect net new
busi million y/i comp cancel rate
histor average albeit less compar backlog burn
rose bp compar prior year period end
backlog billion climb y/i basi vs
estimate gross margin fell bp bp plan
continu hire sg drop bp continu oper leverag
bp ahead plan ebitda margin fell bp bp
plan flow million fund million acquisit
molecularmd million share repurchas million qtd
million capit expenditur reserv stand million
share regain momentum share ytd vs
 iclr share move higher tomorrow follow
upsid disproportion guidanc bump call revenu growth
vs prior ep vs prior
consensu area focu conf call includ
natur book capit alloc activ sh repo
qtd site network relationship ep iclr trade
slight discount cro peer view warrant
given evid continu market share gain capit deploy
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
icon public limit compani icon ireland-bas contract
servic pharmaceut biotechnolog medic devic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario iclr assum substanti
new busi win addit project award offset
sizabl cancel increment profit margin expans
pronounc strength spend outsourc demand
grey sky scenario iclr assum greater-than-
expect declin busi largest custom increas
consolid capit deploy misstep weaken demand
outsourc
 close
result iclr net-btb cc top-line growth demonstr
continu healthi book respect strength non-pf busi
note repres total revenu vs compar
basi contribut percentag point top-line growth await
greater clariti underli dynam confer call tomorrow backlog burn
rise bp compar prior year period littl histor
context basi note industri broadli experienc
deterior backlog convers trend recent year attribut prolong start-up
phase certain larger client along broader impact larger studi matur
increas work complex oncolog project cancel rate
quarter long term histor averag fulli compar due
new account standard repres million
headcount increas sequenti yoy employe driver
gross margin pressur declin bp yoy bp estim
sg leverag continu dilig cost structur effort iclr mainstay declin
bp yoy bp better plan ebitda margin declin bp bp
plan
note iclr execut million share buyback share
disclos addit million buyback qtd share also close
acquisit molecularmd million bolster lab busi
conjunct ep print iclr rais guidanc top bottom
line updat outlook call ep previou
guidanc revenu billion
compar billion previous
factset compani data credit suiss estim dollar million except per share amount
charl martineau pm univers toronto figur backlog convers continu impact increas mix complex therapeut area
iclr backlog convers rate present basi therefor less compar
compani data credit suiss estim note industri averag adjust vari definit recognit backlog less aggress depend
compani
figur book-to-bil ratio strong
iclr btb present basi therefor less compar
iclr report dso current stand day consid
normal rang day longer term gener million cash
cash reserv current stand million net cash posit
million expect capit deploy prioriti includ share buyback
 opportun offer potenti upsid estim
iclr share current trade ep peer group clinic
fulli reflect growth prospect well capit deploy
driver broadli view iclr well-posit benefit continu strong
fundament across cro industri view increment upsid warrant
forecast iclr total revenu increas billion fuel
increas custom diversif new busi win ep forecast
predic ebitda margin deterior bp contribut
share repurchas
forecast revenu rise continu win execut
backlog ep forecast predic ebitda margin
expans bp continu share repurchas
iclr share current trade ep estim premium histor
averag fulli reflect growth prospect capit deploy driver
target price equal ep forecast better reflect
opportun continu market share gain slightli temper diminish pfizer
contribut profit margin leverag opportun potenti upsid capit
deploy option lowest leverag ratio cro univers
charl martineau pm univers toronto compani mention price
